Challenges And Opportunities When Manufacturing High-Concentration Biotech Drugs

Monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and recombinant proteins are growing increasingly important as therapeutics for a variety of treatments including cancer, diabetes, and autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).

As the applications continue to expand for these therapeutics, producing these drugs in a format that can be administered to patients subcutaneously presents significant advantages compared to IV infusion.

Explore opportunities to enhance your platform for high-concentration/subcutaneous drug production.